Buy VRTX by Oct 10, 2026.

**TL;DR** * **\~98%** of Vertex's product revenue still comes from cystic fibrosis drugs. * That franchise came from a **2001** acquisition. The first drug out of it wasn't approved until **2012**, and it didn't become a giant until **\~2019**. * The newer bets (Diabetes, Duchenne Muscular Dystrophy, Kidney disease) are all still pre-revenue. It just paid **\~$10B** cash for **Crinetics**. * The tension: Patient franchise-builder, or serial buyer of pipelines that don't pay off? \------------------ **\~98%** Vertex's revenue still comes …